Theriva Biologics (NYSEAMERICAN:TOVX) Releases Quarterly Earnings Results

Theriva Biologics (NYSEAMERICAN:TOVXGet Free Report) posted its earnings results on Monday. The company reported ($0.19) EPS for the quarter, reports.

Theriva Biologics Trading Up 4.0 %

Theriva Biologics stock opened at $0.41 on Thursday. Theriva Biologics has a 52-week low of $0.20 and a 52-week high of $1.26. The firm has a market cap of $6.95 million, a P/E ratio of -0.34 and a beta of 1.51.

Hedge Funds Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Geode Capital Management LLC bought a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVXFree Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 116,301 shares of the company’s stock, valued at approximately $81,000. Geode Capital Management LLC owned about 0.77% of Theriva Biologics as of its most recent filing with the Securities and Exchange Commission. 5.91% of the stock is currently owned by institutional investors.

About Theriva Biologics

(Get Free Report)

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.

Further Reading

Earnings History for Theriva Biologics (NYSEAMERICAN:TOVX)

Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with's FREE daily email newsletter.